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ABSTRACT

Drug screening targets and method of screening for potential
drugs for treatment or amelioration of Alzheimer’s Disease
are provided.
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DRUG SCREENING TARGET FOR
ALZHEIMER’S DISEASE AND METHOD OF
SCREENING POTENTIAL DRUGS
CROSS-REFERENCE TO RELATED
APPLICATION

[0001] This application is a divisional of US. patent appli
cation Ser. No. 13/423,239, ?led Mar. 18, 2012, which claims

the bene?t of US. provisional patent application 61/453,703,
?led Mar. 17, 2011, each of which is incorporated herein by
reference in its entirety.
FIELD OF THE INVENTION

[0002] This invention relates to the ?eld of drug targets
relevant to the etiology, study, and treatment of Alzheimer’s
disease and to methods for screening chemical compounds to
determine their potential utility for treatment or amelioration
of Alzheimer’s Disease.

SUMMARY OF THE INVENTION

[0005] The present invention provides compositions and
methods for discovering molecules that have the potential to
interfere with the DR6-GFD NAPP interaction, thus treating
or ameliorating AD.
[0006] In one aspect, the present invention is directed
towards a polypeptide whose amino acid residues have about

30% homology to residues 38-123 of the growth factor-like

domain (GFD) of the N-terminal APP fragment (NAPP). The
polypeptide adopts a speci?c conformation in vivo character
ized by having seven beta strands. In addition, the residues
66-81 of the polypeptide adopt a lone alpha-helix motif.
Finally, residue 62 of the polypeptide is Cysteine, residue 71
is Glutamine, residue 74 is Glutamine, residue 82 is Isoleu
cine, residue 103 is Lysine, and residue 123 is Valine. In other
aspects, the invention is directed to such a polypeptide whose

amino acid residues have about 40%, about 50%, about 75%,
about 90%, or 100% homology to residues 38-123 of the
NAPP.

[0007]
BACKGROUND

[0003]

In another aspect, the present invention is directed

towards a polypeptide whose amino acid residues have about
30% homology to residues 96-167 of Death Cell Receptor 6

Alzheimer’s disease (AD) is a degenerative a?Iic

tion of the nervous system that negatively impacts a person’ s

memory, cognitive functions, and ability to perform the nor
mal activities of daily living. The disease also causes behav
ioral problems with which the families of those with the
disease must cope. Typically, AD reduces the lifespan of an
individual by increasing an af?icted person’s risk of suc
cumbing to secondary infections and illnesses. AD will
become increasingly common during the next three decades

as the American populationiin particular, the “baby-boom”
generationiages. It is estimated that by 2035, when the
average age of the baby boom generation is 85, up to 50% of
Americans will have developed AD. Alzheimer’s disease is
associated with the accumulation of beta-amyloid plaques in
the brain that lead to the eventual destruction of brain cells.
The primary cause of AD may be ?aws in the metabolic

processes governing production, accumulation, or disposal of
the beta-amyloid protein fragments. Therefore, treatments for

(DR6), including a ?rst Cysteine Rich Domain (CRD) with at
least 30% homology to amino acid residues 96 to 131 of DR6
and a second Cysteine Rich Domain (CRD) with at least 30%
homology to amino acid residues 133 to 167 of DR6. The

polypeptide adopts a speci?c conformation in vivo character
ized by having twelve beta strands. In addition, residue 98 of
the polypeptide is Arginine, residue 104 is Glutamate, residue
131 is Cysteine, residue 132 is Threonine, residue 139 is
Glutamine, residue 163 is Threonine, and residue 167 is Argi
nine. In other aspects, the invention is directed to such a

polypeptide whose amino acid residues have about 40%,
about 50%, about 60%, about 75%, about 85%, or 100%
homology to residues 96-167 ofthe DR6.
[0008] In another aspect, the present invention is directed
toward methods for screening chemical compounds to deter
mine their potential to modulate or bind to DR6 to prevent or
inhibit its binding to GFD NAPP or to bind to GFD NAPP to

AD often have focused on dissolving beta-amyloid or pre

prevent or inhibit its binding to DR6. In still another aspect,
the present invention is directed toward methods for screen

venting the aggregation of the beta-amyloid fragments into
plaque formations.

ameliorate or retard the onset of AD.

[0004]

ing chemical compounds to determine their potential to treat,

Recently, a novel molecular mechanism to account

BRIEF DESCRIPTION OF THE FIGURES

for axonal pruning and neuronal cell death during physiologi
cal development has been described. It is further hypoth

[0009]

esized that the new mechanism has implications for the patho

crystal structure with key residues highlighted.

physiology

of AD.

According

to

their proposed

developmental model, tropic factor deprivation results in
amyloid precursor protein (APP) proteolysis, culminating in
the release of an N-terminal APP fragment (NAPP) into the
extracellular milieu. NAPP then serves as a ligand for death

cell receptor six (DR6), a member of the tumor necrosis factor

receptor (TNFR21) family. Binding to the DR6 ectodomain
results in the subsequent downstream activation of caspase-3

and caspase-6, respectively, resulting in accelerated neuronal
apoptosis, neuronal degeneration, axonal degeneration, and
the physiological sculpting of nerve connections in the devel

oping brain. It is proposed that this physiological pathway
could be hijacked in the adult brain, resulting in AD. The
DR6-GFD NAPP protein-protein interaction, then, is a key
event in the pathway described, and possibly in the progres
sion of AD.

[0010]

FIG. 1 is a ribbon representation of the GFD NAPP

FIG. 2 is a ribbon representation of the re?ned DR6

ectodomain homology model.
[0011] FIG. 3 is a ribbon representation for the best DR6
GFD NAPP model.

[0012]

FIG. 4 shows the sequence alignment and secondary

structure of the growth factor-like domain of human N-ter

minal APP (GFD NAPP, SEQ ID NO: 1) andAPLP2 (SEQ ID
NO: 3).
[0013]

FIG. 5 shows ribbon representations of GFD NAPP

along with 22C11 interface residues (a), ClusPro predicted
interface residues (b), and PPI-Pred predicted interface resi
dues (c).
[0014] FIG. 6 shows sequence alignment and secondary
structure of the human DR6 ectodomain (SEQ ID NO: 2) and

its homolog, p75 (SEQ ID NO: 4).
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[0015]

FIG. 7 shows ribbon representations of the DR6

ectodomain homology model (a), ClusPro predicted (b), and
PPI-Pred predicted interface residues (c).

involves automatic template selection, fragment reassembly
of aligned regions, ab initio modeling of unaligned regions,
clustering, energy evaluation and the optimization of a mod

[0016] FIG. 8 shows the ?nal DR6-GED NAPP-docked
structure (a), ?nal structure of the DR6-NGF NAPP complex

el’s hydrogen bonding network. Ultimately, the top ranked

(b), DR6-GED NAPP hydrogen bonds and salt bridges (c),
and rigid body association of the DR6-NGF NAPP complex

supplied by the bound crystal coordinates of the neurotrophin
receptor p75 in complex with the neurotrophin (NGF) ligand

(d).
[0017] FIG. 9 shows a comparison of the p75-NGF crystal
structure with the best re-docked p75-NGF model.
[0018] FIG. 10 shows the observed and predicted interface
residues for the p75 receptor derived from the x-ray struc
tures, with interface residues (a), ClusPro predicted interface
residues (b), and PPI-Pred predicted interface residues (c).
[0019] FIG. 11 shows the NGF ligand, with interface resi
dues (a), ClusPro predicted interface residues (b), and PPI

Pred predicted interface residues (c).
[0020]

FIG. 12 shows the model structure of p75-GED

NAPP.
DETAILED DESCRIPTION OF THE INVENTION

[0021] One aim of the present invention is to construct a
theoretical model of the DR6-GED NAPP interaction that
will lead to the discovery of compounds useful for the treat
ment or amelioration of AD. A DR6-GED NAPP interaction

model is constructed using homology modeling, rigid-body
docking and free energy scoring. Calculations and model
predictions are compared, to the extent permitted by the avail

able data, with experimental results and independently gen
erated theoretical results. The ?nal model is analyzed to indi
cate the physical basis of DR6-GED NAPP recognition,
especially within the context of known TNFR interactions.
[0022] The crystal structure of residues 28-123 of GFD
NAPP has been solved at 1.8 A resolution. The structure is

available in the Protein Data Bank (PDB) (http://www.pdb.
org/) with PDB identi?er “1 mwp.” The high quality of the
GED NAPP crystal structure is veri?ed using standard tools.
Comparison with a second, lower resolution but bound NAPP
dimer structure (PDB identi?er “3ktm”) indicates that the 1

I-TASSER DR6 model is selected based on the template

(PDB code: lsgl, chain X). For further analysis and eventual
docking, it is necessary to employ the p75 template (identi?ed
by the I-TASSER server due to its sequence homology with
DR6) since the structure of the DR6 ectodomain is unavail

able. The p75 ectodomain shares good sequence identity with
the DR6 sequence. Like DR6, p75 is a transmembrane pro
tein, is a member of the TNFR family (TNFR16), plays a role
in apoptosis and in AD, and is known to bind NAPP.

[0025] Thus, like the DR6 ectodomain the p75 ectodomain
is stabilized by numerous disul?de bonds and is organized
into several cysteine-rich domains (CRD) that is seen to play
a role in binding. The p75-NGF interaction has also been the

subject of previous modeling and docking studies. Thus,
using p75 as a template structure, we are able to construct a

high quality and binding competent homology model of the
DR6 ectodomain. The sequence alignment and secondary
structure of the human DR6 ectodomain and p75 are depicted
in FIG. 6.
[0026]

FIG. 2 shows a ribbon representation of our energy

optimized and re?ned DR6 ectodomain homology model.
Table 1 summarizes an evaluation of the model by using a
variety of computational tools. The ectodomain of DR6 com
prises residues 67-211. The model is constructed using the
bound coordinates of the p75 receptor and represents a bind
ing competent conformation. The DR6 ectodomain model
takes on a more extended shape and exhibits beta secondary

structure interconnected through less well de?ned structural
elements. The DR6 structure forms a structural depression or
basket region that seems well suited to accommodate a globu
lar protein such as GFD NAPP.

TABLE 1

mwp GFD NAPP structure represents a realistic binding com

petent conformation. As such, the 1 mwp structure is used in
the present study and docked to a homology model of the DR6
ectodomain. The protein models and pictures, with an excep
tion of FIG. 8b which is done in Visual Molecular Dynamics
(VMD) (http://www.ks.uiuc.edu/Research/vmd/), are pre

pared using Swiss PDB Viewer (http://spdbv.vital-it.ch/).
FIG. 1 provides a ribbon representation of the GED NAPP
crystal structure (28-123). GFD NAPP is a high resolution

high quality crystal structure that exhibits a globular fold.
Several key residues (66-81) comprise a lone alpha-helix

DR6

Minimized

Model Quality

I-TASSER
model

DR6 I-TASSER
model

p75 template
structure (1 sgl)

I-TASSER C-score*
I-TAS SER TM-score*
I-TAS SER RMSD*
ProSA Z—Score**
QMEAN Score***
DFIRE Energy****
Minimization

1.31
0.9
2.2
—3.87
0.530
—109.80
N/A

N/A
N/A
N/A
—4.33
0.454
—124.85
—45 64.22

N/A
N/A
N/A
—4.33
0.441
—126.03
N/A

En?rgy>k * * * *

loop motif.
[0023] In order to construct a binding competent theoretical
model of the DR6 ectodomain, a homology modeling pro
gram and/or server may be used. An exemplary embodiment
of such a modeling program and/ or server (which is discussed

*I-TAS SEER server http://zhang.bioinformatics.ku.edu/I-TAS SER/

**ProSA Server https://prosa.services.came.sbg.ac.at/prosa.php

***Qmean Server swissmodel.expasy.org/qmean/
** ** SWISS-MODEL DFIRE http://swissmodelexpasy. org/workspace/

*****TINKER GB/SA AMBER99 minimization (kcal/mol) http://dasher.wustl.edu/ffe/

for consistency and clarity herein is the I-TASSER homology
modeling server (http://zhang.bioinformatics.ku.edu/I
TASSER/). Other representative examples which may be
used include: 3d-jigsaw, Selvita Protein Modeling Platform,

[0027] Homology model construction is typically followed
by visual and quantitative model evaluation. Importantly, the

ROBETTA, Rosetta, CABS, Swiftmodel, LOOPP, RAPTOR,

ous quality scores to assist end-users in model evaluation and

and SPARKSx.
[0024] Towards that end, DR6 residues 67-211 are submit

selection. In particular, I-TASSER calculates an overall target
quality score and a predicted target TM score and RMSD
score. The quality of our DR6 ectodomain homology model is
further assessed according to a Ramachandran map analysis

ted to the I-TASSER server. The I-TASSER server builds

homology models through an exhaustive process that

I-TASSER server automatically calculates and outputs vari
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and through the use of three independent server-based meth

ods: ProSA, Qmean and DFIRE.
[0028] The ProSA server is available at: https://prosa.ser
vices.came.sbg.ac.at/prosa.php. Qmean and DFIRE are
accessed through the SWISS-MODEL server (http://swiss
model.expasy.org/). All three servers use disparate methods
to calculate quantitative scores that can be used to asses

model quality and guide model selection.
[0029] Re?ning the Structure of the

l-TASSER

Ectodomain DR6 Model.

[0030] We use energy minimization, along with the
Amber99 force ?eld and the GB/ SA implicit solvent model,
to re?ne our DR6 ectodomain model. A termination criterion

of 0.5 kcal/mol is applied and convergence is achieved. All
calculations are carried out using the TINKER molecular

O-terminal oxygen atoms, Asp and Glu side-chain carboxyl
oxygen atoms; by default, His is treated as uncharged) and
hydrophobic atoms (C and S atoms), respectively. The third
and fourth terms refer to the total number of hydrogen bonds
and the net number (difference between favorable and unfa

vorable charge-charge contacts) of short-range (54 A)
charge-charge or salt bridge interactions across the protein
protein interface. The contributions of these pairwise inter
face hydrogen bonding and salt bridge interactions are penal
ized according to the degree of solvent exposure, such that if
the average solvent exposure is greater than some experimen

tally derived threshold value, energetic penalties are added to
Eq. (1). The ?nal three descriptors, in order, refer to the
interface gap or void volume, the change in the number of
solvent exposed side-chain torsions or the total number of

modeling package (http://dasher.wustl.edu/tinker/).

side chain torsions buried at the interface, and a constant

[0031]

contribution. Changes in the number of solvent exposed
main-chain torsions can also be counted for peptide ligands.
Theoretical and empirical considerations indicate that Eq. (1)

The energy minimized l-TASSER DR6 ectodomain

homology model is then used in the rigid-body protein-pro

tein docking study.
[0032] One goal is to generate a reasonably accurate model
of the interaction between the DR6 ectodomain and GFD
NAPP. To achieve this goal we use the re?ned l-TASSER

DR6 ectodomain model along with the GFD NAPP crystal
structure as inputs to the ClusPro Docking server, version 1.0

(http://nrc.bu.edu/cluster/cluspro_vl .cgi).
[0033] By default, the ClusPro server docks receptor (DR6)
and ligand (GFD NAPP) structures using version 1.0 of the

DOT rigid-body docking algorithm (http://www.sdsc.edu/
CCMS/DOT/). The top 20,000 complexes generated by DOT
are then ?ltered according to electrostatic and desolvation

energies and the top 2,000 complexes are retained for further
processing. The retained 2,000 conformations are then clus
tered according to interface RMSD and the top 10 docked
models, following a short Charmml9 energy minimization,

will produce accurate absolute binding af?nity predictions
only for receptor-ligand reactions that approximate rigid
body association. Default values are used for each descriptor

and all other important quantities. The model complex with
the lowest empirical free energy score (most negative pre
dicted absolute binding af?nity) is ultimately selected as the
best DR6-GFP NAPP structural interaction model. The

re?nement and scoring procedure is validated using the lsgl
crystal structure.
[0037] A single, physically realistic, DR6-GFD NAPP pre
dicted complex structure is identi?ed. lmportantly, the mod
eling work?ow incorporates extensive a priori testing to

are made available for download. The top 10 ClusPro models

ensure the physical reasonableness and accuracy of the
model. FIG. 3 provides a ribbon representation of the identi
?ed DR6-GFD NAPP interaction model (model 1). The
model indicates an important recognition role for the GFD

capture most of the important rigid-body binding geometries

NAPP alpha-helix-loop motif (residues 66-81). The model

and provide excellent starting structures for further re?ne
ment and analysis. The ClusPro docking methodology is vali

dated using the lsgl crystal structure.
[0034] Ultimately, the top 10 ClusPro models are narrowed
down to a single physically realistic docked con?guration. To

accomplish this, the binding af?nities of the top 10 ClusPro
conformations are estimated in a hierarchical fashion. First,

all 10 complexes are relaxed and optimized through rigid
body energy minimization using the Charmml9 force ?eld.
Next, a pseudo-binding a?inity (AGbl-ndMMGB/SA) is calcu
lated for all 10 models using the Charmml9 molecular-me
chanics force ?eld and GB/ SA implicit solvent model (MM
GB/SA). All calculations are made using TINKER and

default settings. Finally, ClusPro generated complexes with
negative pseudo-binding a?inities (AGMM_GB/SA<0) are
scored using a recently described empirical free energy func
tion that is available through CMDBioscience (http://www.

cmdbioscience.com/).
[0035]

The present invention’s approach to protein-protein

and protein-peptide binding free energy prediction (AGbl-nd,
empirical) involves the use of a novel, fast, physics-based,
empirical free energy function. The function is a six-term,

regression-weighted expression and is given by:
tor

[003 6] The ?rst two terms refer to binding-induced changes
in the total number of solvent-exposed charged atoms (N-ter

minal nitrogen atoms, Arg and Lys side chain nitrogen atoms;

also indicates that the GFD NAPP alpha helix (66-76) rests in
or lines the previously mentioned DR6 structural depression
or basket.

[0038] A priori considerations demonstrated that model 1 is
of probable accuracy. The model is then further tested model
1 a posteriori. Testing is divided into two categories: (1)

biophysical testing and (2) theoretical testing of the model.
The biophysical model testing phase involves binding af?nity
comparisons, the analysis of GFD NAPP and DR6 sequence
alignments, and a comparative analysis with the available
anti-GFD NAPP 22Cl 1 antibody data. The theoretical model

testing phase involves comparisons between data derived
from our DR6-GFD NAPP model and independently gener

ated computational data.
[0039] In addition to binding NAPP, the DR6 ectodomain
binds the N-terminus of APLP2 and with similar af?nity. By
inferring that APLP2 adopts a similar binding con?guration
to DR6 as does GFD NAPP, we further infer that a sequence

alignment betweenAPLP2 and the interface residues of GFD
NAPP will reveal signi?cant conservation. Thus, the pre
dicted interface residues of GFD NAPP are compared,
derived from our DR6-GFD NAPP model, with the aligned

residue positions ofAPLP2. The empirically calculated bind
ing af?nity of the best docked model (—1 1.1 kcal/mol) is in
excellent agreement with the experimentally estimated bind
ing free energy (—1 1.5 kcal/mol). This alignment reveals that
the GFD NAPP interface residues align almost perfectly with
the APLP2 residues that probably mediate binding to DR6.
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This provides indirect evidence that the residue-level contri
bution of GFD NAPP to DR6 binding is captured the model.

[0040] It has also been shown that the NAPP antibody
22C11 interferes with DR6-NAPP binding. Importantly, it

has also been shown that the binding epitope recognized by
the 22C11 antibody spans NAPP residues 66-81. This repre
sents a stretch of residues that are localized aron the lone

helix (66-76) of GFD NAPP. On the inference that 22C11
blocks DR6 binding to NAPP by binding to the same GFD
NAPP surface that mediates DR6 -GFD NAPP interaction, we
compared the GED NAPP interface residues derived from our
model with the GFD NAPP epitope that is known to bind
22011. Once again, that good agreement between the two
indicates veri?cation of the model. Using a 4.5 A cutoff
criterion, the GED NAPP residues that line the DR6-GED
NAPP interface of our model include residues 67, 68, 70, 71,

74, 78, and 79. Thus, there exists excellent agreement
between the experimentally determined 22011 epitope and
the interface residues of our model. Thus, the modeled GFD

TABLE 2
Comparisons between three different methods for predicting
interface residues for GFD NAPP (SEQ ID NO: 1)
ClusPro predicted interface residues for GFD NAPP:

C38, G39, T59, K60, T61, C62, I63, D64, T65, E67, G68, L70,
Q71, Q74, P78, E79, I82, T83, K99, R100, K103,
Q104, E121, F122, V123
PPI-Pred predicted interface residues for GFD NAPP

C38, G39, T61, C62, I63, D64, T65, Q74, P78, E79, I82,
T83, E121, F122, V123
22C11 predicted interface residues for GFD NAPP:

GFD—NAPP amino acid sequence (residues 38—123):

CGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVY
PELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFV

[0044] The ?rst row of Table 2 provides the interface resi
due predictions or contributions of GFD NAPP implied by
our DR6-GFD NAPP ClusPro docked model, using a 4.5 A
inter-chain cutoff criterion. The residues provided in the ?rst
row provide the basis for comparison with the bottom two

NAPP contribution to DR6 binding enjoys further veri?ca
tion and, moreover, focuses attention on the speci?c role

rows. Residue agreement with the ?rst row is thus indicated

played by helix residues 66-76 in DR6-NAPP recognition.

by underlining residues in the bottom two rows. Substantial

[0041]

FIG. 4 shows the sequence alignment and secondary

structure of the growth factor-like domain of human N-ter

minal APP (GFD NAPP) and APLP2; secondary structural
information is also presented. The anti-GFD NAPP (22011)
antibody binding epitope is indicated by a solid black line.
FIG. 5a shows structural models that depict interface residues
derived from the 2201 1 antibody binding experiments. Struc
tural supposition is used to model the p75-NAPP interaction
(FIG. 12) and compare the theoretical estimate of binding

af?nity with the experimental value (Table 1b), thus validat
ing the homology server’s selection of p75 as a template for
secondary structure prediction of DR6.

P75—GFD NAPP

sets veri?es our docked model.

[0045] The second row of Table 2 provides interface resi
due predictions for GFD NAPP that are generated using PPI
Pred. Only PPI-Pred residues that agree with the ClusPro
residues are shown. For GFD NAPP, PPI-Pred predicted two

binding patches (I and II). Patch I has 25 residues; 8 overlap
with the ClusPro interface residues; the ?rst 8 residues above

correspond to patch I. Patch II has 19 residues; 7 overlap with
the ClusPro residues; the last 7 residues are from patch II.
[0046] The third row of Table 2 provides interface residue
predictions for GFD NAPP that are inferred from the fact that
(1) the anti-GFD NAPP antibody 22C11 has a known GFD

NAPP binding epitope (displayed) and (2) that 22C11 blocks

TABLE 1b

Complex

agreement between the three independently generated data

Predicted AGbl-ndyempirim,

Experimental AGbi,l 42,61,

(kcal/mol)

(kcal/mol)

—7.6

—9.0

the interaction between DR6 and GFD NAPP. Thus, we
assume or predict that to block the DR6 interaction 22C1 1 is

binding to the very GFD NAPP epitope that, at least in part,
mediates binding to DR6. Residues that agree with the Clus
Pro predictions are underlined. Finally, the fourth row of
Table 2 lists the primary amino acid sequence of GFD-NAPP

[0042]

The theoretical testing involved a comparison

between the interface residues derived from our docked

model with predicted binding site or interface residues for
GFD NAPP and DR6, respectively, which may be calculated

using the protein-protein interaction prediction server (PPI
Pred) (http://bmbpcu36.leeds.ac.uk/ppi_pred/). From the
coordinates of a monomeric protein structure, PPI-Pred typi
cally predicts two or three binding patches or two or three
well-de?ned residue patches that serve as protein-protein
interaction sites. In the case of GFD NAPP, PPI-Pred pro

duces two patch predictions (I and II); in the case of the DR6

ectodomain, three predicted interface patches result (I, II and
III). The PPI-Pred testing procedure may be validated using
the 1sg1 crystal structure.
[0043]

FIG. 5(b) shows GFD NAPP interface residues

derived from the present docking study; FIG. 5(c) shows
potential interface residues obtained from the PPI-Pred cal
culations. Only the calculated PPI-Pred residues that agree
with the residues obtained from docking study are shown.
These results are summarized in Table 2 below.

(residues 38-123).
[0047]

As in the case of GFD NAPP, DR6 interface residues

derived from the docking study are compared to potential
DR6 interface residues derived from PPI-Pred. Unlike the
case with GFD NAPP, an experimentally derived DR6 inter
face residue set proved to be unavailable. Only the calculated
PPI-Pred residues that agree with the residues obtained from
docking are shown. The results are summarized in FIG. 7 and
in Table 3 below. The evidence indicates that the DR6-GFD

NAPP model is of high quality and probable accuracy.
TABLE 3
Comparisons between two different methods for predicting
interface residues for the homology model of the DR6 ectodomain

(SEQ ID NO: 2)
ClusPro predicted interface residues for DR6 ectodomain homology

model: F96, R98, H99, I103, E104, H107, D108, K120, L121, D128,
E130, C131, T132, C139, N141,A142, K158, E162,
T163, E164, D165, R167

